Co-Inventors
Lenardo, Michael
Swafford, Austin
Shafer-Weaver, Kimberly
Lo, Bernice
Connolly, Amy
Research Products
Research Equipment
Antibodies
The technology at hand represents a pivotal advancement in the early detection of Type 1 Diabetes (T1D) and the associated autoimmune processes. By utilizing electrochemiluminescence (ECL)-based assays, it enables the precise measurement of diabetes-associated antibodies, particularly Insulin Autoantibodies (IAA) in non-obese diabetic (NOD) mice and anti-insulin antibodies (IA) in individuals with Type 1 diabetes. Notably, these assays are non-radioactive, ensuring safety and compliance, while also offering exceptional reproducibility and efficiency. The primary application lies in the early identification of autoimmune insulitis, a crucial precursor to clinical T1D. This technology's potential to contribute to a panel of diagnostic markers holds promise for enhancing predictive diagnoses and supporting future therapeutic trials, ultimately advancing our ability to manage and understand Type 1 Diabetes more effectively.
Commercial Applications
This technology has diverse potential applications. In research, it can identify high-risk NOD mice for preclinical studies. In clinical practice, it enables early diagnosis of T1D by detecting Insulin Autoantibodies (IAA) in at-risk individuals. Furthermore, its adaptability for other diabetic autoantibodies enhances predictive diagnosis, offering valuable insights for research and therapeutic trials in the prevention and management of T1D.
Competitive Advantages
This technology's competitive edge lies in its non-radioactive electrochemiluminescence (ECL)-based assays, ensuring safety and regulatory compliance. Its exceptional reproducibility and efficiency make it a reliable choice for diabetes-associated antibody detection. Most significantly, it excels in early identification of autoimmune insulitis, enabling timely intervention, and its potential for a diagnostic marker panel enhances predictive diagnoses and supports therapeutic trials, making it pivotal in advancing Type 1 Diabetes research and care.
